Author

Lin Chang

EFFICACY AND SAFETY OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF CANNABINOID RECEPTOR 2, FOR THE TREATMENT OF ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A PHASE 2B RANDOMIZED STUDY
EFFICACY AND SAFETY OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF CANNABINOID RECEPTOR 2, FOR THE TREATMENT OF ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A PHASE 2B RANDOMIZED STUDY

EFFICACY AND SAFETY OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF CANNABINOID RECEPTOR 2, FOR THE TREATMENT OF ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A PHASE 2B RANDOMIZED STUDY
EFFICACY AND SAFETY OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF CANNABINOID RECEPTOR 2, FOR THE TREATMENT OF ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A PHASE 2B RANDOMIZED STUDY

Lin Chang  et al.

A NOVEL SCORE TO EVALUATE ABDOMINAL SYMPTOM IMPROVEMENT IN PATIENTS WITH CONSTIPATION-PREDOMINANT IBS DEMONSTRATES EFFICACY OF LINACLOTIDE FOR IMPROVING ABDOMINAL BLOATING, DISCOMFORT, AND PAIN IN A PHASE 3B TRIAL
A NOVEL SCORE TO EVALUATE ABDOMINAL SYMPTOM IMPROVEMENT IN PATIENTS WITH CONSTIPATION-PREDOMINANT IBS DEMONSTRATES EFFICACY OF LINACLOTIDE FOR IMPROVING ABDOMINAL BLOATING, DISCOMFORT, AND PAIN IN A PHASE 3B TRIAL

Lin Chang  et al.

Item 1 - 3 / 3
1